EXACT Therapeutics AS (OSL:EXTX)

EXACT Therapeutics AS Income Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Other Revenue	0.06	-	0	0.45	0.05
Revenue	0.06	-	0	0.45	0.05
Revenue Growth (YoY)	-	-	-99.02%	774.07%	-
Gross Profit	0.06	-	0	0.45	0.05
Selling, General & Admin	28.98	23.36	22.55	14.58	18.52
Research & Development	40.54	18.52	-	-	-
Other Operating Expenses	11.73	8.54	23.74	24.64	38.83
Operating Expenses	84.94	52.85	48.38	41.23	59.16
Operating Income	-84.88	-52.85	-48.38	-40.77	-59.11
Interest Expense	-0.03	-0.05	-0.09	-0.1	-0.1
Interest & Investment Income	2.62	0.92	0.95	0.48	0.34
Currency Exchange Gain (Loss)	-4.68	-0.35	-1.12	0.22	0.01
Other Non Operating Income (Expenses)	0.01	0	0.25	-0.4	0.27
EBT Excluding Unusual Items	-86.97	-52.33	-48.38	-40.57	-58.59
Pretax Income	-86.97	-52.33	-48.38	-40.57	-58.59
Income Tax Expense	-	-	-0.05	-0.46	-
Net Income	-86.97	-52.33	-48.33	-40.1	-58.59
Net Income to Common	-86.97	-52.33	-48.33	-40.1	-58.59
Shares Outstanding (Basic)	63	35	32	30	30
Shares Outstanding (Diluted)	63	35	32	30	30
Shares Change (YoY)	82.42%	8.10%	6.94%	0.06%	0.04%
EPS (Basic)	-1.37	-1.51	-1.51	-1.34	-1.95
EPS (Diluted)	-1.37	-1.51	-1.51	-1.34	-1.95
Free Cash Flow	-72.31	-82.05	-47.39	-34.1	-56.74
Free Cash Flow Per Share	-1.14	-2.37	-1.48	-1.14	-1.89
Gross Margin	100.00%	-	100.00%	100.00%	100.00%
Operating Margin	-143859.87%	-	-1085224.09%	-8971.05%	-113674.66%
Profit Margin	-147402.80%	-	-1084201.23%	-8823.56%	-112673.43%
Free Cash Flow Margin	-122558.79%	-	-1062987.39%	-7503.15%	-109106.39%
EBITDA	-81.81	-51.08	-46.75	-39.3	-57.66
D&A For EBITDA	3.07	1.77	1.63	1.48	1.45
EBIT	-84.88	-52.85	-48.38	-40.77	-59.11
Revenue as Reported	0.06	-	0	0.45	0.05

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.